RHHBYRHHBY
US • —
$51.35
P/E
3.20
PEG
0.06
FCF Yield
—
Rev Growth YoY
+3.0% YoY
Gross Margin
73.9%
Health Score
7/10
D/E Ratio
0.98
Confidence
LOW
Business Snapshot
Roche Holding AG (RHHBY) is a global pharmaceutical and diagnostics company, generating revenue primarily through its prescription medicines (notably in oncology, immunology, and neurology) and its diagnostics division. The company operates in the highly regulated and R&D-intensive healthcare sector, where it holds a position as a dominant player in both pharmaceuticals and in-vitro diagnostics globally. Its market cap tier and exact TTM revenue figures are not available in this data set, limiting a precise scale assessment. A defining characteristic of Roche is its controlling stake held by the Roche family, providing a degree of stability and long-term strategic focus uncommon among large publicly-traded peers.
Financial Health
The company reports a robust gross margin of 73.9%, indicating strong pricing power and efficient production, though a prior-year comparison is not available to assess the trend. The net margin of 13.7% reflects healthy profitability after operating expenses...
Risk Assessment
- VALUATION — The P/E ratio of 3.2x, while low, is so far below the sector average of 22x that it may reflect deep-seated market concerns about future earnings power not visible in trailing data.
- REVENUE DECELERATION — Revenue growth of 3.0% YoY is low compared to the robust earnings growth of 55.4%, suggesting profit growth may not be sustainable if based on one-time factors rather than operational momentum.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- DATA COMPLETENESS — Key financial metrics including TTM revenue, free cash flow, and market capitalization are missing, reducing the transparency and confidence in the fundamental picture....
The company reports a robust gross margin of 73.9%, indicating strong pricing power and efficient production, though a prior-year comparison is not available to assess the trend. The net margin of 13.7% reflects healthy profitability after operating expenses. The balance sheet appears manageable with a debt-to-equity ratio of 0.98x, showing debt is roughly equal to equity, and a current ratio of 1.38x, indicating sufficient short-term liquidity to cover liabilities. Return on equity is exceptionally high at 41.2%, signaling effective use of shareholder capital to generate profits. Free cash flow figures and FCF yield are not available, preventing a full assessment of cash generation capacity.
- VALUATION — The P/E ratio of 3.2x, while low, is so far below the sector average of 22x that it may reflect deep-seated market concerns about future earnings power not visible in trailing data. - REVENUE DECELERATION — Revenue growth of 3.0% YoY is low compared to the robust earnings growth of 55.4%, suggesting profit growth may not be sustainable if based on one-time factors rather than operational momentum. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. - DATA COMPLETENESS — Key financial metrics including TTM revenue, free cash flow, and market capitalization are missing, reducing the transparency and confidence in the fundamental picture.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives